Patent Trends across Oncolytic Virotherapy-Genetic Alert

USD 1,500

* Required Fields

USD 1,500


Be the first to review this product

This edition of the Genetic Alert depicts the current patent landscape and the new life sciences trends across oncolytic virotherapy. Analyst insights on oncolytics viral therapies are also included.

The Genetic Alert presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: cancer therapeutics, oncolytic viral therapies, clinical trials, reovirus therapy, tumor, ovarian cancer, companion imaging

Table of Contents

Patent Trends across Oncolytic Virotherapy-Genetic AlertPatent Trend-Based ProfilesOncolytic Viruses and Virotherapy a Rapidly Evolving Space in the Future of Cancer Therapeutics Genelux Corporation has the Highest Number of Granted PatentsKey Granted Patents from the Top Applicants (2012 to 2016) Key Granted Patents from the Top Applicants (2012-2016) Oncolytic Viral Therapies Entering Late Stage Clinical TrialsReovirus Therapy shows Statistical Significance in Reducing Tumor Burden among Ovarian Cancer PatientsCompanion Imaging Modality Works Synergistically with Oncolytic Viral TherapyStrategic PerspectivesStrategic TrendsAppendixIndustry Interactions




Related Research

Release Date : 12-Jan-18

Region : Global

Release Date : 05-Jan-18

Region : Global

Release Date : 29-Dec-17

Region : Global

Release Date : 29-Dec-17

Region : Global

Release Date : 22-Dec-17

Region : Global

Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.